Lyell Immunopharma, Inc. Common Stock
LYELLyell Immunopharma, Inc. is a biotechnology company focused on developing cell therapies to treat cancer. Founded with a focus on advancing T-cell engineering, Lyell aims to create durable and effective immune-based treatments by leveraging its proprietary platform technologies. The company's approach involves designing and manufacturing next-generation T-cell therapies to improve patient outcomes in oncology.
Company News
Lyell Immunopharma announced updated safety data for ronde-cel, its dual-targeting CD19/CD20 CAR T-cell therapy, showing no Grade ≥3 cytokine release syndrome and low Grade ≥3 neurotoxicity rates in over 100 patients with relapsed/refractory large B-cell lymphoma. Translational data revealed enhanced memory potential of CAR T cells and durabl...
Lyell Immunopharma announced positive safety data for LYL273, its GCC-targeted CAR T-cell therapy for metastatic colorectal cancer. Gastrointestinal prophylaxis significantly reduced Grade ≥2 diarrhea/colitis from 55% to 10%, with no Grade ≥3 cytokine release syndrome or neurotoxicity observed. The Phase 1 trial has been amended to Phase 1/2 ...
Lyell Immunopharma closed an additional $50 million tranche from its $100 million equity private placement following achievement of a clinical milestone for rondecabtagene autoleucel (ronde-cel) in its PiNACLE pivotal trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Office...
Century Therapeutics announced the appointments of Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, bringing extensive experience in biotechnology, corporate development, and life science investment.
Lyell Immunopharma reported promising clinical trial results for ronde-cel, a CAR T-cell therapy targeting large B-cell lymphoma, showing high response rates and a manageable safety profile across multiple treatment lines.
